rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Heartbeam, Inc.

BEAT · Nasdaq

Health CareMedical DevicesNot moving yet

BEAT stood above a rising 150-day average in 5 of the last 52 weekly readings, and has been out of that trend for the last 38 weeks. It is 41.9% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 38
Industry in uptrend
27% -7 in 4 wk
Insider buys, 12 months
$1.9M
Insider sales, 12 months
$1.1M
Officials’ trades on record
0
Institutions holding
42 (+5)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 5 of 52 weeks.

20 Apr – 19 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$970K$0$1.8MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months9
Sale orders, 12 months3
Buyers · sellers8 · 2
WhoDidSharesTraded
Mark E. StromeDirectorbought750,000at $0.8016 Apr 2026filed 16 Apr 2026
Marga Ortigas-WedekindDirectorbought25,000at $0.8016 Apr 2026filed 16 Apr 2026
Robert Paul EnoPresidentbought12,500at $0.8016 Apr 2026filed 16 Apr 2026
Richard FerrariDirectorbought62,500at $0.8016 Apr 2026filed 16 Apr 2026
Branislav VajdicDirectorbought31,250at $0.8016 Apr 2026filed 16 Apr 2026
Michael R. JaffDirectorbought31,250at $0.8016 Apr 2026filed 16 Apr 2026
Willem ElfrinkDirectorbought187,500at $0.8016 Apr 2026filed 16 Apr 2026
Tim CruickshankCFObought31,250at $0.8016 Apr 2026filed 16 Apr 2026
Richard FerrariDirectorbought57,500at $0.8016 Apr 2026filed 24 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders42+5 on the quarter
New · exited11 · 6
Reported value$6.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,137,512$1.6M+939,719+78.5%
BlackRock, Inc.added · filed 7 Aug 2026987,837$741K+89,516+10.0%
CORSAIR CAPITAL MANAGEMENT, L.P.new · filed 14 Aug 2026912,500$684K+912,500
Bleichroeder LPnew · filed 13 Aug 2026625,000$469K+625,000
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026479,386$360K+102,174+27.1%
Smith Salley Wealth Managementunchanged · filed 23 Jul 2026367,647$276K00.0%
UBS Group AGreduced · filed 13 Aug 2026298,917$224K-36,272−10.8%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026274,818$206K+124,756+83.1%
Sigma Planning Corpadded · filed 7 Aug 2026247,700$186K+115,150+86.9%
Beacon Pointe Advisors, LLCreduced · filed 18 Aug 2026247,058$185K-400−0.2%
31 Mar 2023 – 30 Jun 2026
172941Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

George de Urioste Company insiderDirector · last 2 Oct 20260 · 18
Kenneth Warwick Nelson III Company insiderDirector · last 2 Oct 20260 · 0
Marga Ortigas-Wedekind Company insiderDirector · last 2 Oct 20262 · 0
Michael R. Jaff Company insiderDirector · last 2 Oct 20261 · 0
Richard Ferrari Company insiderDirector · last 2 Oct 20263 · 0
Willem Elfrink Company insiderDirector · last 2 Oct 20261 · 0
Branislav Vajdic Company insiderPresident · last 24 Jul 20261 · 0
Kenneth Harry Persen Company insiderChief Technology Officer · last 24 Jul 20260 · 0
Tim Cruickshank Company insiderCFO · last 24 Jul 20262 · 0
Mark E. Strome Company insiderDirector · last 16 Apr 20261 · 1
Robert Paul Eno Company insiderPresident · last 16 Apr 20261 · 0
Richard Brounstein Company insiderChief Financial Officer · last 10 Feb 20232 · 0

Same industry

RCEL Avita MedicalLeading+100%
HAE HaemoneticsLeading+48%
ATRC AtriCureLeading+47%
HTFL HeartflowLeading+47%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 11 Mar 202652.4%
Cash and equivalentsFY 2025 · to 31 Dec 2025$4.4M
Free cash flowFY 2025 · to 31 Dec 2025−$14.6M

Analyst forecasts

No analyst forecasts yet.